List view / Grid view
Non-small cell lung cancer (NSCLC)
US researchers found high levels of XBP1s in lung cancer cells, which plays a key part in regulating the local immune environment in lung tumours, and can be disabled to increase anti-cancer immunity
In this article, Dr Jens Bjørheim, Chief Medical Officer of Ultimovacs, explains why vaccination has proved the best strategy to target human telomerase and why this complex may be an effective approach to combat cancer.
Researchers have discovered that in mice with cancers in the liver, immunotherapy and radiotherapy prevented T-cell death.
A new study has suggested that the enzyme GFPT2 could be a useful target for non-small cell lung cancer (NSCLC).
According to the study, the transcription factor IRF4 drives T cell differentiation and immunosuppression in multiple human cancers.
Researchers have slowed the spread of a type of non-small cell lung cancer in mice by neutralising a protein that would otherwise cause tumour growth.
Researchers have used fullerene compounds to cause NSCLC cell death in cell and animal models, which exhibited low toxicity for healthy cells.
A study has discovered the mechanism behind NSCLC resistance to chemotherapy, which could improve treatment strategies for the condition.